Biotech RadarJobs updated

COMPANY

Edgewise Therapeutics

HQ: Boulder, CO source · edgewisetx.com ↗ · Mountain

Clinical Phase 2

14 open jobs · last seen Oct 23, 2026 · 19 sources

Keywords: cardiovascular cardiovascular disease cardiovascular diseases Becker Muscular Dystrophy Duchenne Muscular Dystrophy Muscular Dystrophies Heart Failure With Preserved Ejection Fraction Hepatic Impairment Hypertrophic Cardiomyopathy Renal Impairments Atrophic Muscular Disorders Muscular Diseases Musculoskeletal Diseases Neuromuscular Diseases Nervous System Diseases Inborn Genetic Diseases EDG-7500 Sevasemten EDG-5506 EDG-15400

Profile checked Oct 10, 2026

Since the raise (Apr 2, 2025): 14 of 14 open jobs were first seen after it.

14Open jobs$200.0MRaised (2 yrs)17Trials (company is sponsor)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Senior Manager / Associate Director, Regulatory CMCUSOct 9, 2026Oct 10, 2026
Associate Director, Technical OperationsUSOct 9, 2026Oct 10, 2026
Corporate ParalegalUSSep 24, 2026Oct 9, 2026
Director, Cardiovascular Field Medical Affairs - EuropeEUSep 23, 2026Oct 9, 2026
Director, Clinical Operations - EuropeEU / Location FlexibleSep 23, 2026Oct 9, 2026

See all 14 jobs

Trial and FDA signals

Job counts as of Oct 18, 2026. All trial and FDA signals

Timeline

  1. Board tracked Radar started tracking this company’s job board (14 open jobs at last check). source ↗
  2. Trial start Phase 2: A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF) source ↗
  3. Trial start Phase 1: A Study to Evaluate EDG-7500 in Caucasian and Japanese Adults source ↗
  4. Trial start Phase 1: A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment source ↗
  5. Trial start Phase 1: A Study of EDG-15400 in Healthy Adults source ↗
  6. Trial start Phase 1: A Study to Evaluate EDG-7500 in People With Renal Impairment source ↗
  7. Raise Follow-on offering: $200M (total, as published), announced Apr 2, 2025. Source: SEC filing. source ↗
  8. Trial start Phase 1: A Study to Evaluate Effect of Verapamil and Food of Sevasemten in Healthy Volunteers source ↗
  9. Trial start Phase 1: A Study to Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C]-EDG-7500 source ↗
  10. Trial start Phase 2: A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM) source ↗
  11. Trial start 2: Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy source ↗
  12. Trial start Phase 2: Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy source ↗
  13. Trial start Phase 1: A Study of EDG-7500 in Healthy Adults source ↗
  14. Trial start Phase 1: Absorption, Metabolism, Excretion and Absolute Bioavailability of EDG-5506 in Healthy Volunteers source ↗
  15. Trial start 2: Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON) source ↗
  16. Trial start Phase 2: A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX) source ↗
  17. Trial start Phase 1: A Study to Assess the Feasibility of Non-invasive Dried Blood Sampling source ↗
  18. Trial start Phase 1: A Study of EDG-5506 in Adult Males With Becker Muscular Dystrophy source ↗
  19. Trial start Phase 1: A Study to Assess Safety, Tolerability, and PK of EDG-5506 in Healthy Volunteers and Becker Muscular Dystrophy Adults source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 14

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Senior Manager / Associate Director, Regulatory CMCUSOct 9, 2026Oct 10, 2026Senior
Associate Director, Technical OperationsUSOct 9, 2026Oct 10, 2026Senior
Corporate ParalegalUSSep 24, 2026Oct 9, 2026Mid
Director, Cardiovascular Field Medical Affairs - EuropeEUSep 23, 2026Oct 9, 2026Senior
Director, Clinical Operations - EuropeEU / Location FlexibleSep 23, 2026Oct 9, 2026Senior
Associate Director, Clinical Operations - EuropeEU / Location FlexibleSep 23, 2026Oct 9, 2026Senior
Associate Director, Scientific CommunicationsUSSep 21, 2026Oct 9, 2026Senior
Associate Director/Director Cardiovascular PharmacologyBoulder, COSep 9, 2026Oct 9, 2026Senior
Cardiac Ultrasound Technician (Associate Scientist/ Scientist)Boulder, COSep 9, 2026Oct 9, 2026Mid
Systems Administrator IIIBoulder, COSep 9, 2026Oct 9, 2026Mid
Executive/Senior/Medical Science Liaison (MSL) – Field Medical Affairs - Geography - Mid-WestUSJul 24, 2026Oct 9, 2026Mid
Executive/Senior/Medical Science Liaison (MSL) – Field Medical Affairs - Geography - WestUSJul 24, 2026Oct 9, 2026Mid
Clinical ScientistUSJul 23, 2026Oct 9, 2026Mid
Clinical Trial Manager/ Senior ManagerUSJun 29, 2026Oct 9, 2026Senior

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Funding

Raised: $200.0M. Last 2 years.

Clinical trials (lead sponsor) 17

RecordTitlePhaseStatusStartPrimary completion
NCT05291091Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)2CompletedNov 10, 2022Sep 7, 2026 (actual)
NCT06066580Open-Label Extension of EDG-5506 in Participants With Becker Muscular DystrophyPhase 2Enrolling by invitationNov 2, 20232031-02 (estimated)
NCT07795814A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)Phase 2RecruitingAug 25, 20262027-12 (estimated)
NCT07177066A Study of EDG-15400 in Healthy AdultsPhase 1CompletedAug 20, 2025Apr 29, 2026 (actual)
NCT07324616A Study to Evaluate EDG-7500 in Adults With Hepatic ImpairmentPhase 1CompletedJan 26, 2026Apr 7, 2026 (actual)
NCT07456059A Study to Evaluate EDG-7500 in Caucasian and Japanese AdultsPhase 1CompletedMar 10, 2026Jun 1, 2026 (actual)
NCT06347159A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)Phase 2Active, not recruitingApr 11, 20242027-12 (estimated)
NCT07034768A Study to Evaluate EDG-7500 in People With Renal ImpairmentPhase 1CompletedJul 22, 2025Dec 22, 2025 (actual)
NCT05540860A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)Phase 2Active, not recruitingOct 24, 20222027-01 (estimated)
NCT06100887Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy2Active, not recruitingMar 22, 20242027-03 (estimated)
NCT05160415A Study of EDG-5506 in Adult Males With Becker Muscular DystrophyPhase 1CompletedDec 28, 2021Mar 1, 2024 (actual)
NCT06738836A Study to Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C]-EDG-7500Phase 1CompletedDec 3, 2024Jan 17, 2025 (actual)
NCT06916897A Study to Evaluate Effect of Verapamil and Food of Sevasemten in Healthy VolunteersPhase 1CompletedJan 8, 2025Feb 22, 2025 (actual)
NCT06011317A Study of EDG-7500 in Healthy AdultsPhase 1CompletedAug 14, 2023May 23, 2024 (actual)
NCT05730842Absorption, Metabolism, Excretion and Absolute Bioavailability of EDG-5506 in Healthy VolunteersPhase 1CompletedJan 12, 2023Apr 6, 2023 (actual)
NCT05492734A Study to Assess the Feasibility of Non-invasive Dried Blood SamplingPhase 1CompletedAug 12, 2022Aug 19, 2022 (actual)
NCT04585464A Study to Assess Safety, Tolerability, and PK of EDG-5506 in Healthy Volunteers and Becker Muscular Dystrophy AdultsPhase 1CompletedOct 12, 2020Nov 15, 2021 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Connect

See your connections at Edgewise Therapeutics on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18

Feedback